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A B S T R A C T
Background: HIV-infection, tuberculosis and malaria are the big three communicable diseases that plague
sub-Saharan Africa. If these diseases occur as co-morbidities they require polypharmacy, which may lead to
severe drug–drug-geneinteractions andvariation inadversedrug reactions,but also intreatmentoutcomes.
Polymorphisms in genes encoding drug-metabolizing enzymes are the major cause of these variations, but
such polymorphisms may support the prediction of drug efficacy and toxicity. There is little information on
allele frequencies of pharmacogenetic variants of enzymes involved in the metabolism of drugs used to treat
HIV-infection, TB and malaria in the Republic of Congo (ROC). The aim of this study was therefore to
investigate the occurrence and allele frequencies of 32 pharmacogenetic variants localized in absorption
distribution, metabolism and excretion (ADME) and non-ADME genes and to compare the frequencies with
population data of Africans and non-Africans derived from the 1000 Genomes Project.
Results: We found significant differences in the allele frequencies of many of the variants when comparing
the findings from ROC with those of non-African populations. On the other hand, only a few variants
showed significant differences in their allele frequencies when comparing ROC with other African
populations. In addition, considerable differences in the allele frequencies of the pharmacogenetic variants
among the African populations were observed.
Conclusions: The findings contribute to the understanding of pharmacogenetic variants involved in the
metabolism of drugs used to treat HIV-infection, TB and malaria in ROC and their diversity in different
populations. Such knowledge helps to predict drug efficacy, toxicity and ADRs and to inform individual and
population-based decisions.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Background
HIV/AIDS, tuberculosis (TB) and malaria, the big three killlers,
are diseases with high prevalences and considerable mortality in
many developing countries. The world-wide prevalence of these
diseases is over 250 million, with sub-Saharan Africa accounting
for 71%, 25% and 92% of HIV/AIDS, TB and malaria, respectively
(Chaudhry et al., 2016). As in many other sub-Saharan African
countries, transmission of the malaria-causing parasite Plasmodi-
um falciparum is high in the Republic of Congo (ROC) (WHO,
2015b), together with a high burden of TB and HIV-infection
(Linguissi et al., 2017). These diseases overlap almost completely,
leading to a high rate of concurrent occurrence of HIV/TB, TB/
malaria and HIV/TB/malaria; however, incidences vary widely
between individuals and communities. Comorbidities require a
polypharmaceutical approach, which may lead to drug–drug-gene
interations and drug-induced pathology, variations in adverse drug
reactions (ADR) and therapeutic efficacy as well as the develop-
ment of drug resistances (Alomar, 2014; Bassi et al., 2017; Rattan
et al., 1998; Turner and Wainberg, 2006). It has recently been
reported that the 25 most common drugs causing ADR in Africa are
drugs used to treat TB, malaria and HIV-infections (Rajman et al.,
2017).
Treatment of TB involves combinations of drugs to be taken
over an extended period of time and in HIV-infection, the
respective drug combinations are taken lifelong. The first-line
treatment of HIV-infection includes highly active antiretroviral
(HAART) drugs, with dolutegravir, efavirenz, raltegravir and
nevirapine being recommended by WHO (2019). Standard first-
line TB treatment consists of isoniazid, rifampicin, pyrazinamide
and ethambutol for two months, followed by isoniazid and
rifampicin for another four months. For the treatment of un-
complicated malaria, artemisinin combination therapies (ACTs)
such as artesunate-amodiaquine, artemether-lumefantrine and
other combinations are the most commonly used drugs used in
sub-Saharan Africa (WHO, 2015a). When multiple drugs are
administered, the treatment outcomes, in particular the efficacy,
ADRs and the degree of emergence of drug resistance vary at the
individual and population level. These variations are influenced by
the age, sex and weight of patients, dosage, comorbidities and
genetic factors. It is known that up to 95% of variations in treatment
outcomes can be explained by genetic factors alone (Ross et al.,
2012). Genetic studies at the population level and the 1000
Genome Project Phase 3 indicate that African ethnic groups are the
most genetically diverse populations (Tishkoff et al., 2009).
Regional allele frequencies of African genomes also show a high
degree of variation (Gurdasani et al., 2015; Ramos et al., 2014).
Genetic variations in drug absorbtion, distribution, metabolism
and excretion (ADME) genes both within and between populations
can influence the pharmacokinetics and pharmacodynamics of
drugs (Ma et al., 2002; Wilson et al., 2001) and lead to differences
in treatment outcomes, drug resistance and increased toxicity (Li
et al., 2011). Pharmacogenomic studies of drugs used to treat the
three diseases have been extensively conducted and variants in
ADME and non-ADME genes have been found associated with
treatment outcomes and toxicity. Some of the common genes
include CYP2B6, CYP3A5, CYP3A4, CYP2A6, ABCB1, NR1I3, UGT2B7,
NAT2, CYP2E1, GSTMI, GSTTI, SLCOB1B1 and UGT1A9 (Bains, 2013;
Chaudhry et al., 2016). While translation of pharmacogenetic
information into clinical practice has been slow, pharmacoge-
nomic drug labels are increasingly being approved by the US Food
and Drug Administration (FDA), the European Medicines Agency
(EMA), Swiss Agency of Therapeutic Products (Swissmedic) and
the Pharmaceuticals and Medical Devices Agency, Japan (PMDA)
(Whirl-Carrillo et al., 2012).
There are very few studies (Peko et al., 2019a, b) available so far
on the allele frequencies of pharmacogenetic variants associated
with the outcomes of the drugs used to treat the three big diseases
in the Republic of Congo (ROC). The main objective of the present
study is to identify allele frequencies of recognized pharmacoge-
netic variants that are associated with treatment outcomes of HIV/
AIDS, TB and malaria in the ROC and to compare the frequencies
with those in other African and non-African populations. Such
knowledge helps to predict drug efficacy, toxicity and ADRs and
inform individual and population-based decisions.
Materials and methods
Study population
Ethical approval was obtained from the Institutional Ethics
Committee of the Fondation Congolaise pour la Recherche
Médicale in Brazzaville, ROC. Following written informed consent
from parents/guardians, a total of 67 children aged between one
and ten years with fever were included randomly out of a cohort
which was recruited for a previous study at the Marien Ngouabi
Hospital in the north of Brazzaville (Etoka-Beka et al., 2016;
Gampio Gueye et al., 2019). Two millilitres of venous blood were
available in EDTA tubes stored at !20 "C.
SNP variants and selection criteria
SNPs with functional and clinical significance for drugs used to
treat HIV-infection, TB and malaria were selected from the
Pharmacogenomics Knowledge Base (PharmGKB; www.
pharmgkb.org). SNPs with allele frequencies >10% known to occur
in African populations based on the data from 1000 Genome
Project were considered in our study.
The custom ordered TaqManTM SNP panel which was designed
and applied included 32 SNPs located in 18 ADME and non-ADME
genes; (Table 1). ADME genes included those encoding ATP Binding
Cassette Subfamily B Member 1 (ABCB1), cytochrome P450 family
(CYPs) CYP2A6, CYP2B6, CYP2D6, CYP2C19, CYP2C8, CYP3A4, CYP3A5,
N-acetyltransferase 2 (NAT2), solute carrier organic anion trans-
porter family member 1B1 (SLCO1B1), UDP-glucuronosyltransfer-
ase family (UGT1A1). Non-ADME genes included those encoding
glucose-6-phosphate dehydrogenase (G6PD), nuclear factor Kappa
B subunit 1 (NF-kB1), tumor necrosis factor (TNF-α), nuclear
receptor subfamily 1, group I, member 2 (NR1I2), cut like
homeobox 2 (CUX2) and ATP/GTP binding protein like 4 (AGBL4).
DNA isolation, genotyping and quality control
Genomic DNA was extracted from the blood samples using the
QIAamp DNA Minikit (Qiagen, Hilden, Germany) according to the
manufacturer's instructions. The quantity and quality of DNA was
determined with the NanoDropTM (Thermo Fisher Scientific Inc.)
and QubitTM 4 Fluorometer using the QubitTM dsDNA BR Assay Kit
(Thermo Fisher Scientific, Waltham, MA, USA). DNA concentrations
ranged between 1!40 ng/mL. Genotyping of the 32 SNPs (Thermo
Fisher assay IDs; Supplementary Table 1) were performed by allele
discrimination with TaqMan1 SNP Genotyping Assays on a Thermo
QuantStudio5TM Real-Time 384 well PCR system (Thermo Fisher
Scientific, Life Technologies, Carlsbad, USA) according to the
manufacturer's protocol. 5 mL final reaction volume was used with
a recommended DNA concentration of 0.2 ng/mL. Data obtained
was loaded into the TaqMan1 Genotyper Software (Thermo Fisher,
Life Technologies, Carlsbad, USA) to automatically retrieve the
genotyping data. Hardy–Weinberg Equilibrium (HWE) was calcu-
lated and only SNPs that passed underwent statistical analysis.
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Data analysis
Five SNPs failed in the assessment of Hardy–Weinberg
Equilibrium (HWE). The allele frequencies of the remaining 27
SNPs were compared with those of non-African and African
populations derived from data of the 1000 genome phase 3 project
(www.ensembl.org). This database includes data of non-African
populations, namely of mixed American (AMR), East Asian (EAS),
European (EUR) and South Asian (SAS) groups and of African (AFR)
populations. The latter include Yoruba in Ibadan, Nigeria (YRI),
Luhya in Webuye, Kenya (LWK), Gambian in the West Coast Region,
The Gambia (GWD), Mende in Sierra Leone (MSL), Esan in Nigeria
(ESN), Americans of African descent in the South-West of the USA
(ASW) and people of African-Caribbean descent from Barbados
(ACB). Pairwise comparisons of genotypes among the populations
were done using Fisher's exact test, taking into account a p-value of
<0.05.
Results
Using a custom-designed panel of SNPs we genotyped in 67
samples 32 SNPs localized in 12 ADME and 6 non-ADME genes
which are known to have pharmacokinetic and pharmacodynamic
relevance for drugs used to treat TB, HIV/AIDS and malaria. Details
of all SNPs, genes, drug substrates and their pharmacogenetic
relevance are given in Table 1. The allele frequencies of the 32
variants are shown in Table 2. Five out of the 32 SNPs failed in the
assessment of HWE (CYP2B6*6, CYP2D6*10, rs1050828 and
Table 1
ADME and non-ADME gene variants with clinical significance in drugs used to treat malaria, tuberculosis and HIV-infection.
Gene SNP ID Defining SNP Phenotype/Association HIV, TB and Malaria drug
substrates
Refs
Absorption, distribution, metabolism and excretion (ADME)
ABCB1 rs1045642 ABCB1*6_3435C>T (I1145I) Null Rifampicin, Efavirenz,
Nevirapine, Nelfinavir,
Atazanavir and Ritonavir
Ciccacci et al. (2010); Park et al. (2010); Yimer
et al. (2011)
rs3842 ABCB1_c193A>G (3'UTR) Not defined Efavirenz Elens et al. (2010)
CYP2A6 rs28399433 CYP2A6*9_-48T>G (Promoter) Reduced function Efavirenz Shahi et al. (1990); Soeria-Atmadja et al.
(2017)
CYP2B6a rs28399499 CYP2B6*18_c.983T>C (I328T) Reduced function Efavirenz and Nevirapine Ciccacci et al. (2013); Gandhi et al. (2012)
rs3745274 CYP2B6*6_c.516G>T (Q172H) Reduced function Efavirenz and Nevirapine Cusato et al. (2016); Sinxadi et al. (2015)
CYP2D6a rs1065852 CYP2D6*10_c.100T>C (S34P) Intermediate function Hydroxychloroquine,
Tafenoquine and Primaquine
Bennett et al. (2013); Saito et al. (2018); St
Jean et al. (2016)
CYP2C19a rs12768009b CYP2C19_c.168+3235G>A
(Intron)
Reduced function Nevirapine Lehr et al. (2011)
rs4244285 CYP2C19*2_19154G>A (P227P) Reduced function Nelfinavir Haas et al. (2005); Kattel et al. (2015)
CYP2C8 rs11572103 CYP2C8*2_c.805A>T (I269F) Reduced function Amodiaquine Parikh et al. (2007)
CYP3A5a rs776746 CYP3A5*3_6986A>G (Splice
defect)
Loss of function Lumefantrine, Atazanavir,
Ritonavir and Nevirapine
Brown et al. (2012); Castillo-Mancilla et al.
(2016); Mutagonda et al. (2017)
rs10264272 CYP3A5*6_14690G>A (K208K) Reduced function
rs41303343 CYP3A5*7_27132insA (-346S) Reduced function
CYP3A4a rs2740574 CYP3A4*1B_-392A>G
(Intergenic)
Reduced function Efavirenz, Atazanavir,
Lumefantrine and Indinavir
Bertrand et al. (2009); Haas et al. (2005); Kile
et al. (2012); Mutagonda et al. (2017)
NAT2a rs1801280 NAT2*5_341T>C (I114T) Slow acetylator function Isoniazid/TB treatment Ben Mahmoud et al. (2012); Chan et al.
(2017); Shi et al. (2015); Singla et al. (2014)rs1799930 NAT2*6_590G>A (R197Q) Slow acetylator function
rs1799929 NAT2*11_481C>T (L161L) Association
rs1208 NAT2*12_ 803A>G (K268R) Fast acetylator function
rs1041983 NAT2*13_282C>T (Y94Y) Fast acetylation function
rs1495741 NAT2_18415371G>A (Tag SNP) Association Isoniazid/TB treatment Chamorro et al. (2016); Ho et al. (2013)
SLCO1B1 rs2306283 SLCO1B1*1b_388A>G (N130D) Enhanced function Rifampicin and Efavirenz Kwara et al. (2014)
rs4149032 SLCO1B1*5_c.85-7793C>T
(Intron)
Reduced function Rifampicin and Isoniazid Calcagno et al. (2019); Chigutsa et al. (2011)
UGT2B7 rs7439366b UGT2B7*2_2100C>T (Y268H) Reduced/Enhanced
function (Substrate
dependent)
Efavirenz Cusato et al. (2016); Kwara et al. (2009)
UGT1A1a rs3064744 UGT1A1*28_ TA (Indel) Reduced function Atazanavir, Dolutegravir,
Ritonavir and Raltegravir
Johnson et al. (2014); Vardhanabhuti et al.
(2015)
rs10929303 UGT1A1_1813C>T (3'UTR) Reduced function Atatanavir and Ritonavir Nishijima et al. (2014)
Non-ADME




Fanello et al. (2008); Sicard et al. (1978)
rs1050829 G6PD_c.376A>G (N126D)
NF-kB1 rs4647992 NF-kB1_c.159+305C>T (Intron) Association TB treatment Zhang et al. (2019)
TNF-α rs1800629 TNF-α _!308G>A (Regulatory) Association Ethambutol, Isoniazid,
Pyrazinamide and Rifampicin
Kim et al. (2012)
NR1I2 rs2472677 NR1I2_63396C>T (Intron) Association Atazanavir, TB and HIV drugs,
and Isoniazid
Calcagno et al. (2019); Schipani et al. (2010);
Siccardi et al. (2008)
CUX2 rs7958375 CUX2_c.64-11987G>A (Intron) Association (GWAS) Rifampicin Petros et al. (2016)
AGBL4 rs319952 AGBL4_c.206+5387T>C (Intron)
rs320003 AGBL4_c.91+2046C>T (Intron)
Note: All SNPs are reported in PharmGKB except rs4647992.
GWAS, genome wide association study.
a Pharmacogenetic labelling for TB/HIV/Malaria drugs approved by US Food and Drug Administration (FDA)/European Medicines Agency (EMA).
b LD SNPs used for genotyping (rs12768009 - rs4986894, rs7439366 - rs7438135, rs3064744 - rs887829).
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rs1050829 [G6PD], rs4647992 [NF-kB1]) and were excluded from
further statistical analysis. Failure of SNPs passing HWE could be
due to the small sample size or errors in genotyping.
Allele frequencies in the ROC and non-African populations
Non-African populations included mixed American (AMR), East
Asian (EAS), European (EUR) and South Asian (SAS) groups.
A pairwise comparison of the allele frequencies observed in
ROC with these four non-African populations revealed significant
differences in allele frequencies for the majority of SNPs tested
(Table 2; p-values in Supplementary Table 2). 18 polymorphisms in
the AMR group and 21 polymorphisms in the EAS, EUR and SAS
populations showed significant differences. In the comparison of
ROC with all non-African populations, the frequencies of 10
polymorphisms were significantly different, namely those of
ABCB1*6, CYP2B6*18, CYP2C8*2, CYP3A5*3, CYP3A5*6, CYP3A5*7,
CYP3A4*1B, SLCO1B1*5, UGT1A1_1813C>T and rs7958375-CUX2.
Significant differences of allele frequencies applied also to 16
polymorphisms in some of the non-African populations only,
namely rs3842-ABCB1 (AMR, EUR), CYP2A6*9 (EAS, EUR),
rs12768009-CYP2C19 (AMR, EAS, SAS), CYP2C19*2 (AMR, EAS,
SAS), NAT2*5 (EAS), NAT2*6 (EAS, EUR, SAS), NAT2*11 (EAS, EUR),
NAT2*12 (EAS, SAS), NAT2_18415371G>A (EAS, EUR, SAS),
SLCO1B1*1b (AMR, EUR, SAS), UGT2B7*2 (EUR, SAS), UGT1A1*28
(AMR, EAS, EUR), rs1800629-TNF-α (AMR, EAS, SAS), rs2472677-
NR1I2 (EAS, EUR, SAS), rs319952-AGBL4 (AMR, EUR, SAS) and
rs320003-AGBL4 (AMR, EUR, SAS). This is in concordance with
published literature (Rajman et al., 2017; Xing et al., 2010), which
describes significant genetic differences between non-African and
African populations.
Allele frequencies in the ROC and other African populations
Other African populations with which comparisons were made
included Yoruba in Ibadan, Nigeria (YRI), Luhya in Webuye, Kenya
(LWK), Gambians in the West Coast Region, The Gambia (GWD),
Mende in Sierra Leone (MSL), Esan in Nigeria (ESN), Americans of
African descent in the South-West of the USA (ASW) and people of
African-Caribbean descent from Barbados (ACB).
Pairwise comparisons of the allele frequencies of the 27 SNPs in
the ROC population with the other African populations were made.
Significant differences were found for only a few of the SNPs
(Table 2; p-values in Supplementary Table 2). In detail, 5
polymorphisms in the ACB group, 3 polymorphisms in ASW, 5
polymorphisms in ESN, 2 polymorphisms in GWD, 5 polymor-
phisms in LWK, 5 polymorphisms in MSL and 4 polymorphisms in
the YRI population showed significant differences of allele
frequencies. Polymorphisms exhibiting significant differences in
comparisons of the ROC with other African populations are rs3842-
ABCB1 (ACB, GWD), CYP2A6*9 (ACB, GWD), CYP2B6*18 (ACB, ESN,
LWK), CYP3A5*3 (ASW), CYP3A5*6 (LWK), NAT2*5 (MSL, YRI),
NAT2*6 (ACB, ASW, ESN, LWK), NAT2*11 (ESN, MSL, YRI) NAT2*13
(ACB, ESN, MSL, YRI), SLCO1B1*5 (ESN), UGT1A1_1813C>T (LWK,
MSL), rs1800629-TNF-α (ACB, GWD), and rs2472677-NR1I2 (MSL,
YRI). As expected, the number of SNPs with frequency differences
in the ROC compared to other African populations was very small.
Despite the low degree of differences, there are enormous
Table 2
Allele frequencies of 32 SNPs in Republic of Congo genotyped and allele frequencies in non-African and African populations from the 1000 Genome Project phase 3 data.
Gene SNP ID Risk Allele Non-African populations African populations ROC (Genotyped) HWE (P-values)
AMR EAS EUR SAS AFR ACB ASW ESN GWD LWK MSL YRI
ABCB1 rs1045642 T 43 40 52 58 12!19 15 19 12 19 14 15 13 17 0.4
rs3842 G 16 30 14 18 4!25 4 17 17 12 25 16 15 24 0.06
CYP2A6 rs28399433 G 10 24 7 15 6!11 6 11 10 6 9 7 10 14 0.51
CYP2B6 rs28399499 C 1 0 0 0 6!12 6 10 7 10 6 8 12 16 0.74
rs3745274 T 37 22 24 38 35!41 38 35 41 35 36 35 40 36 0.02a
CYP2D6 rs1065852 T 15 57 20 17 4!16 15 16 9 12 4 17 11 8 0.01a
CYP2C19 rs12768009 A 10 37 15 37 14!23 16 14 22 14 23 19 17 19 0.79
rs4244285 A 11 31 15 36 13!21 15 14 21 13 21 18 17 19 0.79
CYP2C8 rs11572103 A 1 0 0 1 14!24 21 15 20 24 14 17 20 21 0.13
CYP3A5 rs776746 G 20 29 6 33 69!89 75 69 89 77 88 88 83 84 0.86
rs10264272 A 2 0 0 0 5!24 12 5 14 16 24 16 17 11 0.15
rs41303343 AA 0 0 0 0 9!14 11 12 9 14 12 14 12 12 0.27
CYP3A4 rs2740574 G 10 0 3 4 66!83 66 67 77 79 83 83 76 75 0.96
NAT2 rs1801280 C 36 4 45 35 24!36 28 31 27 34 36 24 24 36 0.75
rs1799930 A 17 26 28 36 19!29 26 29 26 19 27 22 20 16 0.47
rs1799929 T 34 4 44 32 17!33 25 26 19 28 33 19 17 29 0.69
rs1208 G 37 4 44 36 35!46 38 36 39 44 46 35 37 46 0.51
rs1041983 T 29 44 31 43 39!53 50 45 53 39 43 50 50 36 0.75
rs1495741 A 65 48 76 78 51!67 59 67 56 57 66 54 51 63 0.39
SLCO1B1 rs2306283 A 53 24 60 45 12!25 21 25 12 19 16 19 19 17 0.45
rs4149032 C 61 40 66 49 19!36 30 36 19 23 28 27 28 24 0.82
UGT2B7 rs7439366 T 32 28 49 40 18!28 28 25 24 19 25 18 21 25 0.4
UGT1A1 rs3064744 (TA)8 36 13 29 40 38!46 43 42 40 38 46 41 46 47 0.44
rs10929303 T 22 13 23 17 32!50 46 39 50 47 32 33 45 46 0.3
G6PD rs1050828 A 1 0 0 0 4!21 13 17 16 4 18 7 21 19 <.0001a
rs1050829 G 3 0 0 0 28!38 33 29 35 36 34 28 38 40 <.0001a
NF-kB1 rs4647992 T 3 4 5 4 8!24 10 9 10 8 24 8 10 9 0.03a
TNF-α rs1800629 A 7 6 13 5 7!14 14 7 13 14 9 16 10 18 0.34
NR1I2 rs2472677 T 48 62 66 57 28!42 42 35 36 38 40 28 36 48 1
CUX2 rs7958375 G 98 100 100 99 76!86 83 86 85 84 79 76 81 80 0.19
AGBL4 rs319952 T 51 67 40 46 63!80 70 63 71 80 67 78 74 73 0.47
rs320003 C 51 67 40 46 64!80 69 64 75 80 74 80 74 73 0.6
Bold and underlined: statistically significant (P < 0.05, Fisher exact test) pairwise camparison with congo population (P-values in Supplementary Table 2).
African (AFR), Yoruba in Ibadan, Nigeria (YRI), Luhya in Webuye, Kenya (LWK), Gambians in the West Coast Region, The Gambia (GWD), Mende in Sierra Leone (MSL), Esan in
Nigeria (ESN), Americans of African Ancestry in SW USA (ASW), African Caribbeans in Barbados (ACB), Mixed American (AMR), East Asian (EAS), European (EUR), South Asian
(SAS) and Republic of Congo (ROC).
a Failed Hardy–Weinberg equilibrium (HWE).
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differences in allele frequencies between all African populations as
can be seen in the AFR column of Table 2, which shows the lowest
and highest allele frequencies for all genetic variants. For example,
the allele frequency of rs3842 SNP ranges from 4% to 25%. For some
SNPs the allele frequencies among African populations do not
differ significantly however, due to the high burden of disease this
may lead to considerable differences in treatment efficacy and drug
toxicity.
Discussion
In this study, we performed Taqman genotyping assays of SNPs
located in 18 genes in 67 samples of febrile children recruited in
ROC (Etoka-Beka et al., 2016; Gampio Gueye et al., 2019).
CYP variations
Cytochromes P450 (CYPs) are a well characterized family of
phase 1 drug metabolising enzymes involved in the metabolism of
70–80% of drugs. Polymorphisms in these genes are
associated with altering the pharmacokinetics of several drugs
and leading to ADRs (Phillips et al., 2001) or suboptimal clinical
outcome. CYP2B6*6 and CYP2B6*18 alleles exhibit reduced
enzymatic activity and increased plasma concentrations of
efavirenz and nevirapine, which may lead to ADRs (Ciccacci
et al., 2013; Cusato et al., 2016; Gandhi et al., 2012). Due to its
clinical significance, CYP2B6*6 is approved for efavirenz drug
labelling by FDA/EMA/Swissmedic/PMDA (Whirl-Carrillo et al.,
2012). Studies have shown that in patients with the CYP2B6*6
homozygous allele, reduction in the daily dose of efavirenz from
600 to 200 mg/day was sufficient to maintain therapeutic levels
and reduce ADRs (Dhoro et al., 2015). The frequency of the
CYP2B6*6 allele in the ROC population is 36%. In this study, this
particular allele CYP2B6*6 failed to pass HWE assessment. A
previous study showed an allele frequency of 55% (Peko et al.,
2019a), which is the highest compared to other African and to non-
African populations.
CYP2C8*2 reduces the enzyme activity and alters the bioavail-
ability of the antimalarial drug amodiaquine, leading to ADRs and
possibly the emergence of drug resistance (Parikh et al., 2007).
Amodiaquine is known to be the drug most commonly associated
with ADRs in Africa (Cavaco et al., 2005; Kudzi et al., 2009). The
allele frequency of this variant in ROC is 21%, and in other African
populations the frequency ranges from 14 to 24%, while it is
virtually non-existent in non-African populations. Since this
variant occurs almost exclusively in African populations, respec-
tive genotyping in cases of ADRs is recommended for ROC as well
as African populations treated with amodiaquine. CYP3A5*3, -*6
and -*7 reduce enzyme function and increase plasma concen-
trations of quinine, lumefantrine, nevirapine and atazanavir
(Brown et al., 2012; Castillo-Mancilla et al., 2016; Mutagonda
et al., 2017).
The CYP2A6*9 variant reduces enzyme activity and increases
plasma levels of efavirenz (Soeria-Atmadja et al., 2017). This
observation failed to be replicated in some studies. The allele
frequency of this variant in ROC is 14%; the frequencies show
significant differences in other African (6!11%) and non-African
populations (7–24%). The allele frequency in the ROC is highest
among all African populations, suggesting a higher risk of
efavirenz-induced toxicity, and further studies are needed to
strengthen the associations. The CYP2C19*2 and CYP2C19_G>A
variants, which are in linkage disequilibrium, decrease enzyme
function and increase plasma concentrations of nevirapine (Lehr
et al., 2011). Only a few studies have been conducted so far and
further studies are recommended. The allele frequency in ROC is
19% and significant differences among African and non-African
populations were observed. CYP3A4*1B reduces the enzyme
function and increases the plasma concentrations of lumefantrine,
nevirapine atazanavir, and efavirenz (Bertrand et al., 2009; Haas
et al., 2005; Kile et al., 2012; Mutagonda et al., 2017). The frequency
of the CYP3A4*1B allele in ROC is 75% and also high allele
frequencies are seen in other African populations (66!83%)
compared to non-African populations (0–10%). Since African
populations have the highest risk of increasing plasma concen-
trations of drugs metabolized by CYP3A4 and subsequent toxicity;
genotyping and dose adjustment could reduce toxicity and
improve compliance.
NAT and UGT variations
N-acetyltransferase (NAT) and UDP-glucuronosyltransferase
(UGT) are phase II metabolizing enzymes which play a key role
in detoxification of drugs and xenobiotics. Isoniazid is metabolized
by NAT2, and the slow acetylator variants are associated with anti-
TB drug-induced hepatotoxicity (Ben Mahmoud et al., 2012; Chan
et al., 2017; Shi et al., 2015; Singla et al., 2014). Due to its clinical
importance it is approved for pharmacogenetic labelling by FDA.
The NAT2 variants assessed in this study include the slow
acetylation variants NAT2*5 and -*6, the fast acetylation variants
NAT2*12 and -*13, and drug-induced liver injury associated
variants NAT2_tag SNP and NAT2*11. The allele frequency of the
slow acetylator NAT2*5 and -*6 variants in ROC is 36% and 17%,
respectively, and their frequencies vary considerably across
populations. UGT2B7*2, UGT1A1*28 and -*76 cause variable drug
concentrations of efavirenz, atazanavir and ritanovir and toxicity
(Johnson et al., 2014; Nishijima et al., 2014; Vardhanabhuti et al.,
2015). Due to their clinical significance, FDA labelling has been
approved for azatanavir (Du et al., 2019). The allele frequencies of
UGT2B7*2, UGT1A1*28 and UGT1A1_1813C>T variants in ROC are
25%, 47% and 46% respectively. The frequencies vary significantly in
other African populations, ranging from 18 to 28%, 38 to 46% and 32
to 50%, respectively and also differ significantly in non-African
populations. The UGT2B7*2 allele frequency is generally lower in
African than in non-African populations. The UGT1A1*28 and
UGT1A1_1813C>T allele frequencies are higher in African than in
non-African populations.
ABCB1 and SLCO1B1 variations
The P-glycoprotein (P-gp), encoded by ABCB1 and the solute
carrier organic anion transporter family member 1B1 protein,
encoded by the SLCO1B1 gene, are transporter proteins which
facilitate transfer of drugs across cell membranes. Variants in these
genes lead to toxicity or inefficacy and drug resistance.
The ABCB1*6, ABCB1_c193A>G, SLCO1B1*1b and SLCO1B1*5
variants are associated with altered efficacy, pharmacokinetics
and toxicity of rifampicin, isoniazid, efavirenz, nevirapine,
azatanavir and ritonavir(Calcagno et al., 2019; Ciccacci et al.,
2010; Elens et al., 2010; Kwara et al., 2014; Park et al., 2010; Yimer
et al., 2011). The allele frequency of ABCB1*6 and c193A>G in ROC is
17% and 24% respectively, and the frequencies differ significantly
between all populations. The most extensively studied variant
ABCB1*6 is associated with altered efficacy and toxicity in the
treatment with anti-HIV and anti-TB drugs.
The frequencies of SLCO1B1*1b and -*5 in ROC are 17% and 24%,
respectively. These variants occur significantly more frequently in
non-African populations compared to African populations,
indicating the relative risk for elevation of rifampicin and efavirenz
plasma concentrations and isoniazid drug-induced toxicity. The
SLCO1BI polymorphisms are common in South Africa and often
associated with increased rifampicin clearance, leading to the
recommendation of dose adaptation (Chigutsa et al., 2011).
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Non-ADME gene variations
The non-absorption, distribution, metabolism and excretion
(non-ADME) variants of G6PD, NF-kB1, TNF-α, NR1I2, CUX2 and
AGBL4 are associated with toxicity and the pharmacokinetics of
anti-HIV, TB and malaria drugs (Calcagno et al., 2019; Fanello et al.,
2008; Kim et al., 2012; Petros et al., 2016; Schipani et al., 2010;
Siccardi et al., 2008).
TNF-α is an inflammatory cytokine, which plays an important
role in drug-induced immune reactions. NR1I2 (PXR) is a
transcription factor that activates transcription of several ADME
genes. CUX2 and AGBL4 gene variants have been found to be
associated with anti-TB drug-induced hepatotoxicity; however, the
causal mechanisms have not been identified so far. The variants
rs1800629 (TNF-α), rs4647992 (NF-kB1), rs2472677 (NR1I2),
rs7958375 (CUX2), rs319952 and rs320003 (AGBL4) are associated
with anti-TB treatment-induced ADRs.
Study limitations include the small sample size, which needed
to be kept small because of cost considerations. Also, variants with
less than 10% allele frequency were not included despite their
clinical significance. This high cutoff was kept, keeping in mind
that most of the studies have low sample sizes and identifying
statistical differences becomes difficult.
Conclusions
We have designed a custom SNP panel and successfully
genotyped distinct pharamacogentic variants in ROC. When
comparing the allele-frequencies of African with non-African
populations, we found variations in allele frequencies among all
populations. This study helps in predicting efficacy and ADRs at the
population and individual level and underlines the importance of
understanding the role and function of pharmacogenetic variants.
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